Gossamer Bio Inc. has provided an update on their ongoing efforts to develop innovative therapies for pulmonary hypertension, with a focus on their lead investigational drug candidate, Seralutinib. This inhaled small molecule inhibitor targets the PDGFR α/β, CSF1R, and c-KIT pathways for the treatment of Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension due to Interstitial Lung Disease (PH-ILD). The company has announced that the Phase 3 PROSERA study for PAH is ongoing, with topline results expected in February 2026, following the positive outcome of the Phase 2 TORREY Study. Additionally, Gossamer plans to initiate the Phase 3 SERANATA study for PH-ILD by activating the first sites in the fourth quarter of 2025. The company holds composition of matter patent protection until 2036, with Orphan Drug Designation from the FDA, EMA, and PMDA in Japan. Gossamer Bio also has a partnership with Chiesi, involving a 50/50 US profit split and ex-US royalties. The company reports a financial position of approximately $213 million in cash, providing a financial runway into 2027. You can access the full presentation through the link below.